EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions

Chenyue Zhang, Chenxing Zhang, Haiyong Wang

Cancer Letters · 2023

DOI: 10.1016/j.canlet.2023.216182 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2023. Verfasst von Chenyue Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai Medical College, Shanghai, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Neoplasms. Die Arbeit wurde bisher 113-mal zitiert (Crossref) und nennt 253 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer treatment has been advanced with the advent of immune checkpoint inhibitors (ICIs) exemplified by anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) drugs. Patients have reaped substantial benefit from ICIs in many cancer types. However, few patients benefit from ICIs whereas the vast majority undergoing these treatments do not obtain survival benefit. Even for patients with initial responses, they may encounter drug resistance in their subsequent treatments, which limits the efficacy of ICIs. Therefore, a deepening understanding of drug resistance is critically important for the explorations of approaches to reverse drug resistance and to boost ICI efficacy. In the present review, different mechanisms of ICI resistance have been summarized according to the tumor intrinsic, tumor microenvironment (TME) and host classifications. We further elaborated corresponding strategies to battle against such resistance accordingly, which include targeting defects in antigen presentation, dysregulated interferon-γ (IFN-γ) signaling, neoantigen depletion, upregulation of other T cell checkpoints as well as immunosuppression and exclusion mediated by TME. Moreover, regarding the host, several additional approaches that interfere with diet and gut microbiome have also been described in reversing ICI resistance. Additionally, we provide an overall glimpse into the ongoing clinical trials that utilize these mechanisms to overcome ICI resistance. Finally, we summarize the challenges and opportunities that needs to be addressed in the investigation of ICI resistance mechanisms, with the aim to benefit more patients with cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalNeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapySignal TransductionB7-H1 AntigenTumor Microenvironment

Stichwörter der Autor:innen

Clinical trialsCombination therapyHostImmune checkpoint inhibitor resistanceTumor microenvironment

Substanzen

Immune Checkpoint InhibitorsAntineoplastic Agents, ImmunologicalB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai Medical College, Shanghai, China.
  • Department of Nephrology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. Electronic address: wanghaiyong6688@126.com.

Zitieren

APA

Zhang, C., Zhang, C., & Wang, H. (2023). Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions. Cancer Letters. https://doi.org/10.1016/j.canlet.2023.216182

Vancouver

Zhang C, Zhang C, Wang H. Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions. Cancer Letters. 2023. doi:10.1016/j.canlet.2023.216182

BibTeX
@article{Zhang2023,
  author = {Zhang, Chenyue and Zhang, Chenxing and Wang, Haiyong},
  title = {Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions},
  journal = {Cancer Letters},
  year = {2023},
  doi = {10.1016/j.canlet.2023.216182}
}
Kostenlos starten →